Tassos Georgiadis
About Tassos Georgiadis
Title: Vice President, Preclinical Development
Tassos Georgiadis holds the position of Vice President, Preclinical Development. In this role, he is responsible for overseeing the early stages of drug development, particularly focusing on virus-mediated gene therapy. He brings extensive expertise in gene therapy vector design and addressing neurodegenerative diseases.
Education and Expertise of Tassos Georgiadis
Tassos Georgiadis has a robust educational background in genetics and molecular genetics. He holds a BSc in Genetics from Queen Mary & Westfield College, an MSc in Human Molecular Genetics from Imperial College University, and a PhD in Molecular Genetics from University College London. His academic credentials reflect his deep expertise in gene therapy vector design and neurodegenerative disorders.
Research on Virus-Mediated Gene Therapy by Tassos Georgiadis
Tassos Georgiadis has dedicated over 18 years to researching virus-mediated gene therapy. His work primarily focuses on AAV gene therapy vector design, aiming to advance treatments for neurodegenerative conditions. His contributions to this field are well-regarded, both in academic and practical contexts.
Professional Background: UCL Institutes and Beyond
Tassos Georgiadis has experience working at the UCL Institute of Child Health and the UCL Institute of Ophthalmology. Here, he concentrated on ocular disorders and the regulation of gene expression. His professional background also includes serving as a Scientific Consultant for Athena Vision, a biotechnology company specializing in gene therapies.
Tassos Georgiadis' Roles in Professional Organizations
Tassos Georgiadis participates actively in professional communities. He serves as an Expert Member on the UK Health Research Authority Research Ethics Committee and has been an elected member of the Board of the British Society for Gene and Cell Therapy. These roles underscore his commitment to the ethical and scientific advancement of gene therapy.